{"id":7766,"date":"2025-05-23T00:41:00","date_gmt":"2025-05-23T00:41:00","guid":{"rendered":"https:\/\/portal.coneqtia.com\/sandoz-lanza-pyzchiva-el-primer-biosimilar-de-ustekinumab-en-europa-disponible-en-pluma-precargada\/"},"modified":"2025-05-23T00:41:00","modified_gmt":"2025-05-23T00:41:00","slug":"sandoz-lanza-pyzchiva-el-primer-biosimilar-de-ustekinumab-en-europa-disponible-en-pluma-precargada","status":"publish","type":"post","link":"https:\/\/portal.coneqtia.com\/sandoz-lanza-pyzchiva-el-primer-biosimilar-de-ustekinumab-en-europa-disponible-en-pluma-precargada\/","title":{"rendered":"Sandoz lanza Pyzchiva\u00ae, el primer biosimilar de ustekinumab en Europa disponible en pluma precargada"},"content":{"rendered":"<p>Pyzchiva<sup>\u00ae<\/sup> est\u00e1 aprobado para el tratamiento de adultos con psoriasis plazas, artritis psori\u00e1sica, enfermedad de Crohn y psoriasis en placas pedi\u00e1trica. Desde Sandoz Europa afirman que este lanzamiento responde a las necesidades reales de los pacientes y mejora la adherencia terap\u00e9utica gracias a su experiencia de administraci\u00f3n m\u00e1s c\u00f3moda y a su dise\u00f1o compacto.<\/p>\n","protected":false},"excerpt":{"rendered":"<div class=\"mh-excerpt\"><p>Pyzchiva\u00ae est\u00e1 aprobado para el tratamiento de adultos con psoriasis plazas, artritis psori\u00e1sica, enfermedad de Crohn y psoriasis en placas pedi\u00e1trica. Desde Sandoz Europa afirman que este lanzamiento responde a las necesidades reales de los <a class=\"mh-excerpt-more\" href=\"https:\/\/portal.coneqtia.com\/sandoz-lanza-pyzchiva-el-primer-biosimilar-de-ustekinumab-en-europa-disponible-en-pluma-precargada\/\" title=\"Sandoz lanza Pyzchiva\u00ae, el primer biosimilar de ustekinumab en Europa disponible en pluma precargada\">[&#8230;]<\/a><\/p>\n<\/div>","protected":false},"author":27,"featured_media":7766,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":[],"categories":[159,4755,2944,72],"tags":[4107,10458,499,7857,10457],"_links":{"self":[{"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/posts\/7766"}],"collection":[{"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/comments?post=7766"}],"version-history":[{"count":0,"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/posts\/7766\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/media\/7766"}],"wp:attachment":[{"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/media?parent=7766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/categories?post=7766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/portal.coneqtia.com\/wp-json\/wp\/v2\/tags?post=7766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}